Healthy volunteers test new MDS drug LP-001 for safety

NCT ID NCT06294275

First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 19 times

Summary

This early-stage study tested LP-001 in 68 healthy adults aged 18-50 to see if it is safe and how the body handles it. The drug is being developed for myelodysplastic syndrome (MDS), a blood disorder. The study gave single and multiple doses to gather key information before testing in patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME (MDS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Shanghai Public Health Clinical Center

    Shanghai, China

Conditions

Explore the condition pages connected to this study.